DS
AMLX icon

David Shaw’s Amylyx Pharmaceuticals AMLX Stock Holding History

David Shaw’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Buy
174,285
+100,055
+135% +$1.55M ﹤0.01% 2808
2026
Q1 		$1.03M Buy
74,230
+1,006
+1% +$14.2K ﹤0.01% 3419
2025
Q4 		$885K Buy
73,224
+4,347
+6% +$59K ﹤0.01% 3618
2025
Q3 		$936K Sell
68,877
-82,625
-55% -$778K ﹤0.01% 3497
2025
Q2 		$971K Sell
151,502
-118,504
-44% -$576K ﹤0.01% 3251
2025
Q1 		$956K Sell
270,006
-36,738
-12% -$131K ﹤0.01% 3109
2024
Q4 		$1.16M Sell
306,744
-384,322
-56% -$1.81M ﹤0.01% 3121
2024
Q3 		$2.24M Sell
691,066
-617,115
-47% -$1.39M ﹤0.01% 2629
2024
Q2 		$2.49M Buy
1,308,181
+265,598
+25% +$515K ﹤0.01% 2463
2024
Q1 		$2.96M Buy
1,042,583
+495,618
+91% +$6.48M ﹤0.01% 2315
2023
Q4 		$8.05M Sell
546,965
-213,325
-28% -$3.27M 0.01% 1528
2023
Q3 		$13.9M Sell
760,290
-829,754
-52% -$17.5M 0.01% 1059
2023
Q2 		$34.3M Sell
1,590,044
-432,326
-21% -$11.7M 0.04% 585
2023
Q1 		$59.3M Buy
2,022,370
+638,638
+46% +$22.2M 0.06% 375
2022
Q4 		$51.1M Buy
1,383,732
+1,221,467
+753% +$43.3M 0.06% 430
2022
Q3 		$4.57M Buy
+162,265
New +$4.05M 0.01% 2196

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's AMLX Position: Q2 2026 in Review

David Shaw increased its Amylyx Pharmaceuticals (AMLX) stake by 135% in Q2 2026, buying an estimated $1.55M and bringing the position to 174,285 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

David Shaw first reported a position in AMLX in Q3 2022 and has held it in 16 quarters since. The position peaked at $59.3M in Q1 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • David Shaw held 174,285 shares of Amylyx Pharmaceuticals worth $3.13M as of Q2 2026.
  • David Shaw bought 100,055 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.55M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2808 holding.
  • David Shaw first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • David Shaw's Amylyx Pharmaceuticals position peaked at $59.3M in Q1 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.